Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology

Aiming for a holistic integrated service for men diagnosed with prostate cancer – Definitions of standards and skill sets for nurses and allied healthcare professionals

“…Recently, attention has focussed on the interdisciplinary and multiprofessional nature of prostate cancer care with proposals for European Prostate Cancer Units. (2) In addition, some units internationally have sought to define standards for nurse-led care in specific treatment domains, for example Robocare (3). We sought to establish a comprehensive set of recommendations for the service structure and skill set of nurses and allied healthcare professionals in prostate cancer care in a referral centre.…”

Verbesserte Behandlung des Prostatakarzinoms in zertifizierten Zentren

“…Dieser sog. "patient reported outcome" (PRO) wird bei [7]. Gleichzeitig werden aber auch die Schwierigkeiten bzw.…”

“…Gleichzeitig werden aber auch die Schwierigkeiten bzw. Defizite in der Datenerfassung und in der intersektoralen Behandlung des Prostatakarzinoms sichtbar [6,7]. Die Entwicklung der Prostatazentren ist ein fließender Prozess und muss sich jährlich an neue Veränderungen in Diagnostik und Therapie anpassen.…”

Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: from 223Ra-dichloride to new horizons for therapeutic response assessment

“…These Bnew^options open the door to a multidisciplinary approach involving strong cooperation between nuclear medicine physicians and other specialists including oncologists, radiation oncologists and urologists, that will allow the development and implementation of diagnostic and therapeutic strategies in patients with PC. This is the most efficient way to guarantee that professionals and structures are available to offer care at all stages to patients with PC, taking into account both the optimized current strategies and futures updates and modifications [4].…”

“…These Bnew^options open the door to a multidisciplinary approach involving strong cooperation between nuclear medicine physicians and other specialists including oncologists, radiation oncologists and urologists, that will allow the development and implementation of diagnostic and therapeutic strategies in patients with PC. This is the most efficient way to guarantee that professionals and structures are available to offer care at all stages to patients with PC, taking into account both the optimized current strategies and futures updates and modifications [4].Until a few years ago, the therapeutic instruments of nuclear medicine in the management of PC consisted of some betaemitting agents for the treatment of bone metastases, such as Ra-dichloride (Xofigo®) is the first targeted α-emitting radiopharmaceutical agent approved for the treatment of patients with metastatic CRPC that has been shown to improve overall survival, and also to delay skeletal-related events (SREs) and better control of bone pain. It selectively binds to areas of increased bone turnover, thus producing nonrepairable double-stranded DNA breaks [5,6], with a potent cytotoxic effect [7][8][9].…”